Listen: Vertex’s polarizing data, Aduhelm’s adieu, & an FDA icon
This week on "The Readout LOUD" podcast: What makes a blockbuster? Can biotech learn from Aduhelm? And how do you replace a singular regulator?
What makes a blockbuster? Can biotech learn from Aduhelm? And how do you replace a singular regulator?
We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. We explain the debate over Vertex Pharmaceuticals’ novel pain drug, whose success in clinical trials comes with a sizable caveat. We also talk about the latest news in the life sciences, including an epitaph for Aduhelm and the retirement of an FDA icon.
What's Your Reaction?
